Who makes V116517 30-mg tablets?

V116517 30-mg tablets is developed by Purdue Pharma LP.

What development phase is V116517 30-mg tablets in?

V116517 30-mg tablets is in Phase 2.

Last reviewed 2026-05-13 · How we verify

V116517 30-mg tablets

Purdue Pharma LP · Phase 2 active Small molecule

At a glance

Generic name	V116517 30-mg tablets
Sponsor	Purdue Pharma LP
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) (PHASE2)
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

V116517 30-mg tablets CI brief — competitive landscape report
V116517 30-mg tablets updates RSS · CI watch RSS
Purdue Pharma LP portfolio CI